# Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites

> **NCT01552590** · PHASE4 · TERMINATED · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 74 (actual)

## Conditions studied

- Hyponatremia and Extracellular Fluid in Cirrhotic

## Interventions

- **DRUG:** Tolvaptan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01552590
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2022-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01552590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01552590, "Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01552590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*